Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
1,857.00    -53.00 (-2.77%)
Bid:
1,863.00
Ask:
1,866.00
Spread: 3.00 (0.161%)
Market Cap: £2.07b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

PLANNING PERMISSION SECURED

20 Apr 2012 11:27

RNS Number : 7549B
Derwent London PLC
20 April 2012
 



 

20 April 2012

 

Derwent London plc ("Derwent London" / "the Group")

 

PLANNING PERMISSION SECURED FOR MAJOR MIXED-USE SCHEME AT 1 OXFORD STREET

 

Derwent London, in collaboration with Crossrail Limited, is pleased to announce that Westminster City Council has passed a resolution to grant permission for a mixed-use scheme at 1 Oxford Street, London W1. The scheme, with a total net lettable area of 275,000 sq ft (25,500m2), will be built above the Tottenham Court Road Crossrail and London Underground Station. It is Derwent London's intention to exercise its option to reacquire the site which was compulsorily purchased by Crossrail in 2009, following the completion of the upgrade works, expected to be in 2017.

 

Working with architects Allford Hall Monaghan Morris, the plans are for two striking buildings overlooking an attractive new public square that links Charing Cross Road to Soho Square. The larger building stands on the corner of Oxford Street and Charing Cross Road and incorporates the station entrance, along with 37,000 sq ft (3,400m2) of retail space and 177,000 sq ft (16,400m2) of offices over eight floors above. Complementing this, to the south is a self-contained 34,000 sq ft (3,200m2) 350-seat theatre, with 27,000 sq ft (2,500m2) of offices above. The theatre has been designed in collaboration with Nimax Theatres, a leading London operator, and offers a highly versatile performance space.

 

John Burns, Chief Executive of Derwent London, commented:

 

"We are delighted that Westminster City Council has approved this important scheme. It will help in the much needed revitalisation of the eastern end of Oxford Street which is essential for the long-term growth of the West End. The Derwent London development will provide high quality office and retail space, together with a new theatre and public realm which promise to become a significant landmark. With its very close proximity to the interchange at Tottenham Court Road, this is another prominent development that will benefit from the arrival of Crossrail."

 

-ends-

 

For further information please contact:

 

Derwent London 020 7659 3000

 

John Burns, Chief Executive Officer

 

Paul Williams, Executive Director

 

Louise Rich, Head of Investor Relations

 

 

Brunswick Group

 

Elizabeth Adams 020 7404 5959

 

 

Notes to editors

 

Derwent London plc

 

Derwent London plc is the largest central London focused REIT with an investment portfolio of £2.6bn as at 31 December 2011. The Group is one of London's most innovative office specialist property regenerators and investors and is well known for its design-led philosophy and creative management approach to development.

 

Derwent London's core strategy is to acquire and own a portfolio of central London property that has reversionary rents and significant opportunities to enhance and extract value through refurbishment, regeneration and redevelopment. The Group owns and manages an investment portfolio of 5.4 million sq ft (501,000m2), as at 31 December 2011, of which 96% is located in central London, with a specific focus on the West End and the areas bordering the City of London. Landmark schemes by Derwent London include Angel Building EC1, Arup Phases II & III W1, Qube W1, Horseferry House SW1, Johnson Building EC1, Davidson Building WC2 and Tea Building E1.

 

Derwent London came fifth overall in the 2011 Management Today awards for 'Britain's Most Admired Companies' and has also recently won the Estates Gazette Property Company of the Year - Offices award. In 2011, Angel Building was shortlisted for the RIBA Stirling Prize following its RIBA London 2011 award and has also won numerous accolades from organisations such as the British Council for Offices, the British Construction Industry and New London Architecture. The Maple & Fitzroy development in Fitzrovia W1, which completed in September 2010, also won a 2011 RIBA London and New London Architecture award.

 

For further information see www.derwentlondon.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBBLFLLZFBBBQ
Date   Source Headline
22nd Sep 202512:00 pmRNSBlock listing Interim Review
9th Sep 202511:45 amRNSDirector Declaration
2nd Sep 202511:30 amRNSHolding(s) in Company
29th Aug 20254:45 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNSBoard Change
12th Aug 20257:00 amRNSInterim Results
5th Aug 20257:00 amRNSNew headlease agreed at 50 Baker Street W1
31st Jul 20254:45 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSDisposal of Francis House SW1 for £55.5m
25th Jul 20257:00 amRNSExtension of £450m Revolving Credit Facility
30th Jun 20254:45 pmRNSTotal Voting Rights
18th Jun 20257:00 amRNSAdobe lease extension and expansion
12th Jun 202511:00 amRNSRedemption of £175 million Convertible Bonds
30th May 20254:45 pmRNSTotal Voting Rights
29th May 202511:15 amRNSHolding(s) in Company
23rd May 20254:05 pmRNS£250m 7-year 5.25% bond issuance
16th May 202512:00 pmRNSResults of 2025 Annual General Meeting
8th May 20257:00 amRNSFirst Quarter Business Update
1st May 202510:00 amRNSAnnual Bondholder Meeting
30th Apr 20254:45 pmRNSTotal Voting Rights
15th Apr 202510:00 amRNSAnnual Financial Report
9th Apr 20253:00 pmRNSAdditional Listing
31st Mar 20254:45 pmRNSTotal Voting Rights
31st Mar 202510:00 amRNSNotice of Q1 2025 Business Update
26th Mar 20251:00 pmRNSDirector/PDMR Shareholding
20th Mar 20254:45 pmRNSBlock listing Interim Review
7th Mar 20252:00 pmRNSDirector/PDMR Shareholding
4th Mar 20255:15 pmRNSDirector/PDMR Shareholding
28th Feb 20254:45 pmRNSTotal Voting Rights
27th Feb 20257:00 amRNSResults for the Year Ended 31 December 2024
31st Jan 20254:45 pmRNSTotal Voting Rights
30th Jan 20255:35 pmRNSHolding(s) in Company
27th Jan 20251:30 pmRNSHolding(s) in Company
9th Jan 20257:00 amRNS25 Baker Street W1 offices fully pre-let
31st Dec 202412:45 pmRNSTotal Voting Rights
3rd Dec 20247:00 amRNSAcquisition
29th Nov 20244:45 pmRNSTotal Voting Rights
7th Nov 20247:00 amRNSTHIRD QUARTER BUSINESS UPDATE
5th Nov 202412:44 pmRNSHolding(s) in Company
31st Oct 20244:45 pmRNSTotal Voting Rights
23rd Oct 20245:30 pmRNSHolding(s) in Company
16th Oct 202410:30 amRNSDirectorate Change
30th Sep 20244:45 pmRNSTotal Voting Rights
20th Sep 20244:45 pmRNSBlock listing Interim Review
19th Sep 202411:00 amRNSDirector/PDMR Shareholding
17th Sep 202411:03 amRNSHolding(s) in Company
30th Aug 20244:45 pmRNSTotal Voting Rights
23rd Aug 202411:15 amRNSAdditional Listing
8th Aug 20247:00 amRNSHalf-Year Results
31st Jul 20244:45 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.